AIML medical imaging technology achieves 98% in FDA trials
A ten-week pivotal clinical trial at TriCore Reference Laboratories in New Mexico during July and August 2015 tested APAS against a panel of microbiologists. Culture plates from 5,500 patients were processed by APAS and simultaneously assessed by a panel of independent qualified microbiologists. The results showed that APAS achieved over 98% sensitivity in its detection of disease-causing bacteria in the samples.
This is a great result for the AIML-developed technology.